Acasti Pharma (ACST) Misses Q1 EPS by 42c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/28/2026
- Wall Street ends higher on revived AI momentum
- Meta's $97.5B AI money grab: why Zuckerberg is racing to raise cash before rivals
- Deutsche Bank’s Reid sees potential final dip this year before Santa rally
- UPS tops estimates as efficiency drive gains momentum
- GM to move stock listing to Nasdaq in November, shares gain
Tweet
Share
E-mailGet Alerts ACST Hot Sheet
Join SI Premium – FREE
Acasti Pharma (NASDAQ: ACST) reported Q1 EPS of ($0.54), $0.42 worse than the analyst estimate of ($0.12).
For earnings history and earnings-related data on Acasti Pharma (ACST) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Lennox (LII) Misses Q3 EPS by 52c, Beats on Revenue; Offers FY26 EPS Guidance
- Otis Worldwide (OTIS) Tops Q3 EPS by 4c, Beats on Revenue; Offers FY26 Guidance
- Smurfit Westrock Plc (SW) Misses Q3 EPS by 15c, Misses on Revenue
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
